Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral

Autor:	M. Dulic, Harald Hofer, Karoline Rutter, Andreas Maieron, AF Stättermayer, Heidemarie Holzmann, Robert Strassl, Petra Steindl-Munda, Peter Ferenci, Sandra Beinhardt, Hermann Laferl, Thomas-Matthias Scherzer, Michael Gschwantler
Rok vydání:	2013
Předmět:	Simeprevir medicine.medical_specialty Hepatology business.industry Ribavirin Balapiravir Danoprevir Gastroenterology virus diseases Telaprevir Surgery chemistry.chemical_compound chemistry Internal medicine Genotype Faldaprevir Medicine Pharmacology (medical) business Mericitabine medicine.drug
Zdroj:	Alimentary Pharmacology & Therapeutics. 38:118-123
ISSN:	0269-2813
DOI:	10.1111/apt.12350
Popis:	BACKGROUND The introduction of direct-acting anti-virals has increased sustained virological response (SVR) rates in chronic hepatitis C genotype 1 infection. At present, data on long-term durability of viral eradication after successful triple therapy are lacking. AIM To evaluate the long-term durability of viral eradication in patients treated with triple therapy, including direct-acting anti-virals. METHODS Patients who participated in randomised, controlled trials or an extended access programme of treatment with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral (telaprevir, danoprevir, faldaprevir, simeprevir, mericitabine, balapiravir) were followed after achieving SVR. The median follow-up after the patients was 21 (range: 7-64) months. RESULTS One hundred and three patients with chronic hepatitis C genotype 1 infection [f/m: 34/69; GT-1b: 67 GT-1a: 34, GT-4: 2; mean age: 47.6 years (45.5-49.7; 95% CI)] achieving a SVR triple therapy were followed. Two cases of late relapses (2/103, 1.9%; 95% CI: 0.24-6.8) were observed. One patient was cirrhotic, both carried the genotype 1b and completed the prescribed treatment. The relapses occurred 8 and 12 months after cessation of anti-viral treatment. Cloning sequencing revealed identical sequence in both patients. Resistance analysis revealed no presence of viral resistance. CONCLUSION Like the SVR after peginterferon-α2/ribavirin combination treatment, HCV eradication after triple therapy remains durable after long-term follow-up.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::013d1b04e9db3d381230f4cdbd6fed5e https://doi.org/10.1111/apt.12350 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.